TAK - Takeda eosinophilic esophagitis asset resubmission accepted by FDA
2023-09-20 08:52:06 ET
More on Takeda Pharmaceutical
- Takeda: Innovative But Volatile, Fairly Priced For The Risk (Downgrade)
- ImmunoGen inks deal with Takeda for cancer drug Elahere
- Takeda pulls marketing application for dengue vaccine in the U.S.
- Seeking Alpha’s Quant Rating on Takeda Pharmaceutical
For further details see:
Takeda eosinophilic esophagitis asset resubmission accepted by FDA